Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Tallies Vytorin Switches: 27% From Zocor, 24% From Lipitor

This article was originally published in The Pink Sheet Daily

Executive Summary

Combined Vytorin and Zetia new prescription share is now 11%, with total prescription share at 10%, Merck reports. Global sales for the drugs were $511 mil. in the first quarter, with $332 mil. from Zetia and $179 mil. from Vytorin.
Advertisement

Related Content

Schering Sees Return To Earnings Growth And "Turnaround" Phase On Horizon
Schering Sees Return To Earnings Growth And "Turnaround" Phase On Horizon
Merck/Schering's Vytorin Priced At 22% Discount To Pfizer's Lipitor
Merck/Schering's Vytorin Priced At 22% Discount To Pfizer's Lipitor

Topics

Advertisement
UsernamePublicRestriction

Register

PS062048

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel